In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioteching UCB-and Maybe Mid-Sized Pharma, Too

Executive Summary

Celltech could not get the deal value it expected for its late-stage anti-inflammatory treatment--perhaps indicating a Big Pharma reluctance to pay the kinds of prices it has been paying. So UCB struck while it could. Led by new management it seized the opportunity to make what is a transforming move for the midsized European company-from undersized primary care group into a specialist, biopharma firm ranked alongside--indeed above--European biotech bellwether, Serono. If it works, the deal provides a model for other mid-sized European pharmas, looking for a way out of the primary care trap and, like UCB, to use mid-size advantages to power a sustainable long-term strategy.
Advertisement

Related Content

European Consolidation: Serious Competition for Big Pharma?
UCB: Will Cimzia Be Enough?
Organon Reboots with Biotech
Pierre Fabre: Time to Reap R&D Rewards In-House
Mid-Sized European M&A Fills Earnings Gap--And More?
Solvay Pharma: Dealing Its Way Into the Limelight
Bayer: Out of Trouble Come Opportunities
Europe's Flavors of Sustainable BioPharma
Are Late-Stage Deals Beginning to Lose Their Luster?
Finding the Opportunities in Aptamers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel